



## Company Announcement

### Nykode Therapeutics - presentation from Capital Markets Day in Oslo

Oslo, Norway, September 27, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today hosts its Capital Markets Day in Oslo.

The presentation slides are available in the Investors section of the Company's website at:

<https://nykode.com/investors/financial-reports-and-presentations/>

The archived webcast of last week's Capital Markets Day in New York, including the presentation by Dr. Bradley Monk, VP and Member of the Board of Directors of the GOG-Foundation, may be accessed on the following link:

[https://event.webcasts.com/starthere.jsp?ei=1633969&tp\\_key=dc0959d03d](https://event.webcasts.com/starthere.jsp?ei=1633969&tp_key=dc0959d03d)

#### **About Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.



### **Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

### **Contact for Nykode Therapeutics ASA:**

Alexandra Deschner, Head of IR  
Nykode Therapeutics ASA  
[IR@nykode.com](mailto:IR@nykode.com)

### **Nykode Therapeutics ASA**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway